Data from the large cardiovascular safety studies with DPP-4 inhibitors (see section below) did not show a respective signal
Some insurers now cover Wegovy specifically for cardiovascular risk reduction in patients with established heart disease and obesity, even when their weight-loss-only formulary excludes it
4 Other than being on GLP-1s, higher risk patients include: those in the dose-escalation phase and those with upper GI symptoms (eg, nausea, vomiting, dyspepsia, abdominal distension, and abdominal discomfort/pain). 4 And obviously, other high-risk group includes patients with comorbidities associated with delayed gastric emptying (eg, poorly controlled diabetes, Parkinsons disease, bowel dysmotility) as well as those on other drugs that slow gastric emptying (eg, opioids, tricyclic antidepressants, marijuana, alcohol)
doi:10.1007/s10815-018-1180-y
Preclinical CagriSema data suggests it may preserve energy expenditure by maintaining mitochondrial function in skeletal muscle, which could theoretically support better muscle preservation over time
In this Monte Nido continuing education session, The Weight of It All: Medications, Messaging & the Risk to Eating Disorder Recovery, Dr
